Stock Update (NASDAQ:ALXN): Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation

[Business Wire] – Alexion Pharmaceuticals, Inc. today announced the initiation of dosing in a single, multinational, placebo-controlled clinical trial to evaluate the efficacy and safety of eculizumab for the prevention of delayed graft . . . → Read More: Stock Update (NASDAQ:ALXN): Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation Similar Articles: Company Update: Johnson & Johnson (NYSE:JNJ) – 9:01 am Johnson & Johnson: Two-year data from INNOVATION trial on INCRAFT AAA stent graft system continues to demonstrate safety and performance in treatment of abdominal aortic Aneurysms Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14 AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial